ACRO today announced that its Board of Directors has elected Peyton Howell, Chief Operating & Growth Officer at Parexel, as Chair of the association effective Jan. 1, 2024. Lisa Moneymaker, Chief Technology Officer & Chief Product Officer at Saama, was elected Vice Chair. In addition, the Board of Directors elected Mike Crowley, Chief Administrative Officer & General Counsel at Parexel, as Secretary of the association and re-elected Ari Feldman, Senior Vice President, Global Compliance and Strategy at Medidata Solutions, as Treasurer.
Ms. Howell joined Parexel in 2018 and most recently was President, Consulting and Chief Commercial & Strategy Officer leading the company to record new business growth and creation of a patient-focused strategy. She has more than 25 years of leadership experience in the healthcare industry and prior to joining Parexel held several leadership positions with AmerisourceBergen — now Cencora (a Fortune 20 company) — most recently as President for Health Systems and Specialty Care Solutions, a $50B business unit. Ms. Howell was a founder of Lash Group, growing the company from an early innovator of patient access services to nearly 5,000 employees and serving as President for nearly 10 years following its acquisition by AmerisourceBergen. She holds a Masters’ in Healthcare Administration (MHA) from The Ohio State University and in 2020 was named a Luminary by the Healthcare Businesswomen’s Association (HBA). Ms. Howell serves on the Board of Directors of Tandem Diabetes Care (NASDAQ: TNDM), a medical device manufacturer, and has represented Parexel on the ACRO Board since 2020.
“Across a challenging geopolitical and economic climate in 2023 ACRO member companies maintained their focus on the patient, adapting and innovating to drive continued transformation in the conduct of clinical trials,” said Ms. Howell. “I am excited to lead the association in the year ahead and to build on this progress as we foster deeper connections and collaboration across the clinical research enterprise to optimize the development of new therapies for patients around the world.”
ACRO is also pleased to announce the addition of Advarra, a site-centric technology company. and YPrime, an eClinical trial management solutions company, as its newest members.
“The addition of YPrime and Advarra to ACRO’s membership reflects ACRO’s continued evolution in representing the CROs and clinical technology companies that support drug development,” said Ms. Moneymaker. “Initiatives like ACRO’s newly formed AI/ML Committee highlight the value of providing a space for leaders from across the clinical research industry to collaborate on the topics that are driving industry change.”
About ACRO
ACRO advocates as the collective voice of innovative clinical research and technology organizations to regulators and policymakers, educating stakeholders and shaping policies that foster the efficient, effective and safe conduct of clinical research.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231213452029/en/
Contacts
ACRO Media Contact
Aislinn Quinn, aquinn@acrohealth.org
